Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E, Clavio M, Arboscello E, Bellodi A, Bruzzone A, Del Corso L, Lucchetti MV, Miglino M, Passalia C, Pierri I, Ponassi I, Oneto C, Racchi O, Scudeletti M, Vignolo L, Zoppoli G, Gobbi M, Ghio R.
Balleari E, et al. Among authors: arboscello e.
Leuk Res. 2011 Nov;35(11):1472-6. doi: 10.1016/j.leukres.2011.05.025. Epub 2011 Jul 26.
Leuk Res. 2011.
PMID: 21794914